These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30219977)

  • 1. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.
    Khan R; Rheaume E; Tardif JC
    Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting IL-1β in the Treatment of Atherosclerosis.
    Mai W; Liao Y
    Front Immunol; 2020; 11():589654. PubMed ID: 33362770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interleukin 1β inhibition in cardiovascular disease.
    Qamar A; Rader DJ
    Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease.
    McCarty S; Frishman W
    Cardiol Rev; 2014; 22(4):176-81. PubMed ID: 24618930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canakinumab for secondary prevention of coronary artery disease.
    Ortega-Paz L; Capodanno D; Angiolillo DJ
    Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
    Ait-Oufella H; Libby P; Tedgui A
    Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities.
    Khambhati J; Engels M; Allard-Ratick M; Sandesara PB; Quyyumi AA; Sperling L
    Atherosclerosis; 2018 Sep; 276():1-9. PubMed ID: 30006321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colchicine: an affordable anti-inflammatory agent for atherosclerosis.
    Thompson PL; Nidorf SM
    Curr Opin Lipidol; 2018 Dec; 29(6):467-473. PubMed ID: 30320614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.